MAPT and early-onset autosomal dominant Alzheimer disease: Over the past ten years, Cerebrospinal Fluid (CSF) biomarkers (β-amyloid (Aβ), total Tau (t-Tau), phosphorylated Tau181 (pTau)) have dramatically improved the accuracy of the molecular diagnosis of Alzheimer’s Disease (AD) in clinical practice.